Division of Vascular and Endovascular Surgery, Department of Surgery, University of California San Diego, La Jolla, CA.
Department of Surgery, State University New York Downstate University Health Sciences University, Brooklyn, NY.
Ann Vasc Surg. 2024 Dec;109:83-90. doi: 10.1016/j.avsg.2024.06.028. Epub 2024 Jul 17.
Thoracic endovascular aortic repair (TEVAR) and complex endovascular aneurysm repair (cEVAR) are effective and minimally invasive treatment options for preventing rupture and decreasing mortality of aortic aneurysms. Patients with renal insufficiency are prone to worse postoperative cardiovascular morbidity and mortality due to the atherosclerosis burden as well as increased levels of angiotensin II. Nonetheless, knowledge about the outcomes of aortic stent graft therapy in patients with chronic kidney disease (CKD) or dialysis is scarce. This study aimed to examine outcomes after TEVAR and cEVAR in patients on CKD and dialysis.
Utilizing data from the Vascular Quality Initiative (VQI) Vascular Implant Surveillance and Interventional Outcomes Network database, we retrospectively evaluated patients who underwent TEVAR or cEVRA from 2010 to 2018. Patients were divided into patients with no CKD or dialysis, CKD patients, and dialysis patients. Outcomes were in-hospital stroke, myocardial infarction (MI), spinal cord ischemia (SCI), 30-day mortality, 1-year mortality, aneurysmal rupture, and reintervention. In-hospital outcomes were assessed using multivariable logistic regression analysis and 1-year outcomes were evaluated using Kaplan-Meier Survival and Cox regression analyses.
A total of 4,867 patients were included in the study, 2,694 had no CKD or dialysis, 2,047 had CKD, and 126 were on dialysis. Dialysis patients were significantly younger, and more likely to be non-White and of Hispanic/Latino origin. They were also more likely to have medical comorbidities. CKD patients had higher odds of in-hospital MI (odds ratio [OR]: 2.02, 95% confidence interval [CI] (1.43-2.86), P < 0.001) and 30-day mortality (OR: 1.56, 95% CI (1.18-2.07), P < 0.001) compared to patients with no CKD or dialysis. Dialysis patients had higher odds of 30-day mortality (OR: 3.31, 95% CI (1.73-6.35), P < 0.001). At 1 year, dialysis was associated with a higher risk of mortality (hazard ratio [HR]: 3.48, 95% CI (2.39-5.07), P < 0.001) and reintervention (HR: 1.72, 95% CI (1.001-2.94), P < 0.049). CKD was associated with a higher risk of mortality (HR: 1.45, 95% CI (1.21-1.75), P < 0.001) compared to patients with no CKD or dialysis.
Among patients undergoing TEVAR or cEVAR, there was no significant difference in the risk of in-hospital stroke, SCI, and 1-year aneurysmal rupture among dialysis and CKD patients compared to patients with no CKD or dialysis. However, CKD patients had twice the risk of in-hospital MI. Dialysis patients had a higher risk of 1-year reintervention. Both dialysis and CKD patients had a higher risk of 30-day and 1-year mortality.
胸主动脉腔内修复术(TEVAR)和复杂的腔内动脉瘤修复术(cEVAR)是预防主动脉瘤破裂和降低死亡率的有效微创治疗选择。肾功能不全的患者由于动脉粥样硬化负担以及血管紧张素 II 水平升高,更容易出现术后心血管发病率和死亡率增加。尽管如此,关于慢性肾脏病(CKD)或透析患者主动脉支架移植物治疗的结果的知识仍然很少。本研究旨在检查 CKD 和透析患者接受 TEVAR 和 cEVAR 后的结果。
利用血管质量倡议(VQI)血管植入物监测和介入结果网络数据库的数据,我们回顾性评估了 2010 年至 2018 年期间接受 TEVAR 或 cEVAR 的患者。患者分为无 CKD 或透析、CKD 患者和透析患者。结果包括院内卒中、心肌梗死(MI)、脊髓缺血(SCI)、30 天死亡率、1 年死亡率、动脉瘤破裂和再次介入。使用多变量逻辑回归分析评估院内结果,使用 Kaplan-Meier 生存和 Cox 回归分析评估 1 年结果。
共有 4867 名患者纳入研究,2694 名患者无 CKD 或透析,2047 名患者患有 CKD,126 名患者正在透析。透析患者明显更年轻,更有可能是非白人且为西班牙裔/拉丁裔。他们也更有可能患有合并症。与无 CKD 或透析的患者相比,CKD 患者的院内 MI(比值比 [OR]:2.02,95%置信区间 [CI](1.43-2.86),P < 0.001)和 30 天死亡率(OR:1.56,95%CI(1.18-2.07),P < 0.001)的可能性更高。透析患者的 30 天死亡率(OR:3.31,95%CI(1.73-6.35),P < 0.001)更高。在 1 年时,透析与死亡率(风险比 [HR]:3.48,95%CI(2.39-5.07),P < 0.001)和再介入(HR:1.72,95%CI(1.001-2.94),P < 0.049)的风险增加相关。与无 CKD 或透析的患者相比,CKD 患者的死亡率(HR:1.45,95%CI(1.21-1.75),P < 0.001)的风险更高。
在接受 TEVAR 或 cEVAR 的患者中,与无 CKD 或透析的患者相比,透析和 CKD 患者的院内卒中、SCI 和 1 年动脉瘤破裂风险无显著差异。然而,CKD 患者发生院内 MI 的风险增加一倍。透析患者的 1 年再介入风险较高。透析和 CKD 患者的 30 天和 1 年死亡率风险较高。